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majority were the closely related, vancomycin-resistant 
[lo] species L. casei, L. paracasei or L. rhamnosus, and 
that the vancomycin-sensitive species L. acidophilus is 
only rarely implicated. 
Probiotics appear to be attractive to the public; 
promotional material makes such claims as ‘maintains a 
healthy digestion’, ‘improves digestibility and assimil- 
ation of food’, ‘keeps intestinal contents sweet’, ‘assists 
general well-being’, and ‘protects skin against harmfd 
microbes’. As, in the UK, probiotics are foods rather 
than medicines, ths type of claim, although virtually 
impossible to substantiate, is allowed. 
There is considerable evidence that lactobacilli may 
be tolerant to p-lactam antibiotics [6,11]; this may have 
led to the failure in the case reported here of the oral 
prophylaxu given before the dental treatment. Toler- 
ance has also been held responsible for treatment failure 
in several cases [6]. The patient described here chewed 
the contents of capsules, which could have increased 
the risk of endocarditis following dental treatment. 
Patients who are immunosuppressed or have pre- 
existing heart valve disease should avoid probiotic 
preparations containing L. rhamnosus, and warnings on 
packaging to this effect should be considered. It is 
noticeable that in the case presently being dscussed, it 
was the L. rhamnostrs rather than the other constituents 
of the probiotic capsules that caused the endocarditis, 
although all the species present had equal opportunity 
to colonize the valve. There appears to be less risk 
attached to the use of probiotic organisms such as 
L. acidophilur (see above) or Lactobacillus sp GG [2]. 
Another probiotic species best avoided is Enterococcus 
faecium (especially if vancomycin resistant [12]), as there 
may be more risks than benefits from its use [13]. 
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In the early 1990s, an increasing number of serogroup 
C meningococcal strains was observed [l], and a rise in 
the incidence of the disease was also found, especially 
in some regions in the northwest of the country, 
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Figure 1 Banding patterns of gmomic DNA from C:3b:P1.1,5 Neisseria metzingitidis isolates obtained with &/I1 
endanuclease (lanes 2, 5-9 isolated from asymptomatic carriers, and lanes 3, 1, 10-14 from patients). Bacteriophage lanibda 
concatemers (lanes 1 and 15) were used as molecular size standard (48.5 kb). 
particularly in Galicia. In this region, the incidence in 
1996 was three times higher than in the previous year 
(1 1 .16/105 inhabitants versus 3.65/105), with sero- 
group C accounting for about 80% of isolates [2]. Since 
then, the situation has spread all around the country, 
affecting most of the regions of Spain [3]. For these 
reasons, the local health authorities in Galicia decided 
to initiate a systematic immunization campaign at the 
end of 1996 [4]. 
At the same time as the immunization campaign, a 
survey of the carriage of Neisseria was made in Galicia, 
in order to determine the prevalence of the C:2b:- 
P1.1,5 epidemic strain in an a.symptomatic population. 
Forty-two meningococcal strains showing this par- 
ticular phenotype were found in 9796 subjects sampled 
(data not shown). Nasopharyngeal swabs were taken 
from all these people immediately before meningo- 
coccal vaccination. 
To determine the genetic variability of this ‘epi- 
demic strain’ we used pulsed field gel electrophoresis 
(PFGE) to analyse those 42 strains isolated from 
asymptomatic carriers and an additional SO meningo- 
coccal strains showing the ‘epidemic phenotype’ 
C:3b:P1.2,5 isolated from patients in Galicia during 
1996 and 1997. The chromosomal DNA from all 
isolates was digested with BglII and analyzed by the 
methods described previously [S]. 
All but three strains showed the same macrorestric- 
tion pattern consisting of 12 bands (Figure l), looking 
identical to the pattern number 2 described previously 
in our laboratory [5]. One strain isolated from an asymp- 
tomatic carrier (lane 3) and two from patients (lanes 3 
and 4) appeared with three different patterns. These 
data indicate a high level of clonality in the C:2b:P1.2,5 
meningococcal strains isolated from patients as well as 
those strains isolated from asymptomatic carriers. This 
may be because these strains are not carried for long 
(perhaps related to the virulence of this C:2b:P1.2,5 
strain), and thus do not have long enough to allow any 
genetic recombination. The other three patterns could 
be genetic variants not yet consolidated. Additional 
studies are necessary to improve our knowledge of the 
evolution of this epidemic strain C:2b:P1.2,5. 
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